Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse

作者全名："Luo, Xiao-Hua; Poiret, Thomas; Liu, Zhenjiang; Meng, Qingda; Nagchowdhury, Anurupa; Ljungman, Per"

作者地址："[Luo, Xiao-Hua] Chongqing Med Univ, Dept Hematol, Affiliated Hosp 1, Chongqing, Peoples R China; [Luo, Xiao-Hua; Poiret, Thomas; Liu, Zhenjiang; Meng, Qingda; Nagchowdhury, Anurupa] Karolinska Inst, Dept Lab Med, Stockholm, Sweden; [Ljungman, Per] Karolinska Univ Hosp, Dept Cellular Therapy & Allogene Stem Cell Transpl, Stockholm, Sweden; [Ljungman, Per] Div Hematol, Stockholm, Sweden; [Ljungman, Per] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden"

通信作者："Luo, XH (通讯作者)，Chongqing Med Univ, Dept Hematol, Affiliated Hosp 1, Chongqing, Peoples R China.; Luo, XH (通讯作者)，Karolinska Inst, Dept Lab Med, Stockholm, Sweden."

来源：FRONTIERS IN IMMUNOLOGY

ESI学科分类：IMMUNOLOGY

WOS号：WOS:000934161700001

JCR分区：Q1

影响因子：7.3

年份：2023

卷号：13

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：cytomegalovirus; WT1=Wilms tumor 1; immune reconstitution; stem cell transplantation; acute myeloid leukemia (AML)

摘要："In allogeneic hematopoietic cell transplantation (allo-HSCT), both virus-specific T cells and leukemia-specific T cells need to be reconstituted to protect patients from virus infections and primary disease relapse. Cytomegalovirus (CMV) infection remains an important cause of morbidity and mortality after allo-HSCT. Emerging data indicate that CMV reactivation is associated with reduced risk of leukemia relapse in patients with acute myeloid leukemia (AML) undergoing allo-HSCT. In a cohort of 24 WT1+ AML patients during the first year following HSCT, CMV specific CD8+ T cells (CMV-CTL) reconstituted much faster than WT1-specific CD8+ T cell (WT1-CTL) after allo-SCT. Moreover, CMV-CTL expressed lower levels of exhaustion markers and were more functional as identified by production of IFN-gamma/TNF-alpha and expression of Eomes/T-bet. Interestingly, our patients with CMV reactivation presented higher frequency of CMV-CTL, lower levels of Eomes+T-bet- and higher levels of Eomes+T-bet+ expression in response to WT1 and CMV pp65 antigen during the first year after transplantation as compared to patients without CMV reactivation. Kinetics of CMV-CTL and WT1-CTL after transplantation might be associated with measurable residual disease and later leukemia relapse. Our results support that CMV reactivation, aside from the CMV-CTL reconstitution, could influence WT1-CTL reconstitution after allo-HSCT, thus potentially contributing to the remission/relapse of AML."

基金机构：　

基金资助正文：